New York, USA:
Gross sales of the Covid-19 vaccine developed by Pfizer and BioNTech may attain as a lot as $ 15 billion in 2021 and improve if Pfizer indicators further provide contracts, Pfizer mentioned Tuesday.
The projections got here when Pfizer projected gross sales for full 12 months 2021 of between $ 59.four billion and $ 61.four billion, which means that a couple of quarter of the full estimated gross sales will come from the Covid-19 vaccine.
The forecast displays “a continued restoration in well being care and macroeconomic exercise all through 2021 as extra populations are vaccinated towards Covid-19,” Pfizer mentioned.
“These assumptions are guided by the trajectory of present an infection charges in lots of elements of the world and the anticipated timeline for broad entry to efficient vaccines.”
Pfizer reported a fourth-quarter web revenue of $ 594 million, in contrast with a lack of $ 337 million in the identical interval final 12 months.
For all of 2020, Pfizer reported earnings of $ 9.6 billion, down 41.four p.c from 2019, with income up two p.c at $ 41.9 billion.
Pfizer’s fourth-quarter income included $ 154 million in gross sales of the Covid-19 vaccine.
The vaccine started gaining approval from authorities late final 12 months. Pfizer mentioned it expects to have the ability to ship as much as 2 billion doses in 2021 primarily based on a number of components, together with including extra contracted suppliers and producers.
Pfizer shares have been up 0.5 p.c to $ 35.94 in pre-market buying and selling.